Combining radioactive therapy with liver treatment for advanced prostate cancer

Plain-English translation of NCT07145177 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a combination treatment for men with advanced prostate cancer that has spread to the liver and stopped responding to standard hormone-blocking drugs. The treatment combines , a radioactive medication that targets cancer cells, with a procedure called liver-directed therapy (either chemoembolization or ablation) that directly treats tumors in the liver. Researchers want to see if using both treatments together is safe and effective.

Some men's prostate cancer becomes resistant to standard hormone treatments and spreads to the liver, which is particularly hard to treat. This trial is exploring whether combining a targeted radioactive therapy with procedures that directly attack liver tumors might work better than either treatment alone.

Do you qualify?

You likely qualify if…

you have been diagnosed with prostate cancer that has spread beyond the prostate and has progressed despite treatment with at least one modern hormone-blocking drug
you have testosterone levels suppressed to castrate levels (either from surgery or ongoing hormone injections)
you have cancer visible on a specific type of scan (PSMA PET scan) that shows at least one spot outside the liver
you have one or more tumors in your liver that can be treated with liver-directed therapy
you are at least 18 years old and in reasonably good overall health (ECOG performance status of 2 or better)
your blood counts, liver function, and kidney function are adequate to safely receive this treatment

You likely don't qualify if…

you have not received prior treatment with a second-generation hormone-blocking drug like abiraterone, apalutamide, darolutamide, or enzalutamide
you have brain metastases that were treated less than 28 days ago
you have severe liver disease or very low blood counts that would make treatment unsafe
you have not recovered from side effects of prior cancer treatments (other than hair loss or mild nerve damage)

What participation looks like

If you qualify, you would receive up to six cycles of the radioactive medication given every 6 weeks, along with one or more sessions of liver-directed therapy timed with your medication doses. Some participants may receive liver-directed therapy before starting the medication, while others may receive it during treatment depending on how their cancer responds. You would have follow-up visits every 3 months for up to 5 years after your last treatment to monitor how you're doing and watch for any side effects.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

Trial locations(1 site)

United States

University of California, San Francisco, San Francisco, California